Department of Radiology, Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Republic of Korea.
Department of Radiology, Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Republic of Korea.
Clin Imaging. 2021 Jul;75:131-137. doi: 10.1016/j.clinimag.2021.01.021. Epub 2021 Jan 20.
Oncotype DX is a multigene assay used in breast cancer, and the result provided as a 'recurrence score (RS)' corresponds to the risk of a cancer recurrence and the chemotherapeutic benefit in estrogen receptor (ER)-positive human epidermal growth factor receptor (HER)2-negative invasive breast cancer. However, its accessibility is limited.
To evaluate whether magnetic resonance imaging (MRI) could be used to predict Oncotype DX RS in patients with ER-positive HER2-negative invasive breast cancer.
We enrolled 473 patients with ER-positive HER2-negative invasive breast cancer who underwent a preoperative MRI and Oncotype DX assay between January 2015 and December 2018. The MRI was reviewed and associations between Oncotype DX RS values were evaluated. Logistic regression analysis was used to identify independent predictors of high and low RS.
Of the 485 cancers, 288 (59.4%) had low (<18), 155 (31.9%) had intermediate (18-30), and 42 (8.7%) had high (≥31) RS. Multiple logistic regression analysis revealed that a round shape (odds ratio [OR] = 2.554, P = 0.089) and low proportion of washout component (OR = 1.011, P = 0.014) were associated with low RS and that heterogeneously dense (OR = 3.205, P = 0.007) or scattered fibroglandular (OR = 3.776, P = 0.005) breast tissue, a non-spiculated margin (OR = 5.435, P = 0.007), and low proportion of persistent component (OR = 1.012, P = 0.036) were associated with high RS.
MRI features showed the potential for the discrimination of Oncotype DX RS in patients with ER-positive HER2-negative invasive breast cancer.
Oncotype DX 是一种用于乳腺癌的多基因检测，其结果以“复发评分（RS）”的形式呈现，反映了雌激素受体（ER）阳性人表皮生长因子受体 2（HER2）阴性浸润性乳腺癌的癌症复发风险和化疗获益。然而，其可及性有限。
评估磁共振成像（MRI）是否可用于预测 ER 阳性 HER2 阴性浸润性乳腺癌患者的 Oncotype DX RS。
我们纳入了 2015 年 1 月至 2018 年 12 月期间接受术前 MRI 和 Oncotype DX 检测的 473 例 ER 阳性 HER2 阴性浸润性乳腺癌患者。对 MRI 进行了回顾性分析，并评估了 Oncotype DX RS 值之间的相关性。采用 logistic 回归分析确定 RS 高低的独立预测因素。
在 485 例癌症中，288 例（59.4%）RS 较低（<18），155 例（31.9%）RS 中等（18-30），42 例（8.7%）RS 较高（≥31）。多因素 logistic 回归分析显示，圆形（比值比 [OR] = 2.554，P = 0.089）和低廓清成分比例（OR = 1.011，P = 0.014）与低 RS 相关，而异质致密（OR = 3.205，P = 0.007）或散在纤维腺体（OR = 3.776，P = 0.005）乳腺组织、非分叶状边缘（OR = 5.435，P = 0.007）和低廓清成分比例（OR = 1.012，P = 0.036）与高 RS 相关。
MRI 特征显示其有可能用于区分 ER 阳性 HER2 阴性浸润性乳腺癌患者的 Oncotype DX RS。
